Advanced therapies, medicines bring new hope for pulmonary hypertension patients: Dr Manisha Mendiratta: Shardul Nautiyal, Mumbai Saturday, February 8, 2025, 08:00 Hrs [IST] Dr Ma ...

"We also await data of the use of sotatercept in post-capillary pulmonary hypertension ([WHO] group ... endothelin receptor antagonist (ERA) and a phosphodiesterase-5 (PDE-5) inhibitor.

Researchers were originally studying sildenafil as a potential treatment for high blood pressure. However, during clinical ...

Pulmonary hypertension and essential hypertension could be the first clinical applications for sGC stimulators, whereas heart failure might be the first clinical application for sGC activators.

This is thanks to an enzyme called phosphodiesterase type 5 ... of their validity. Pulmonary arterial hypertension (PAH) is a serious condition that happens when the tiny vessels in your lungs ...

Objective: To review available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of cilomilast, a selective phosphodiesterase-4 (PDE4) inhibitor.